Vivimed Labs has informed that the board of directors of the company at its meeting held on May 30, 2012, has recommended final dividend of 3.5% on compulsorily convertible and cumulative preference shares (CCPS's) on pro-rata basis for the financial year 2011-12. A final dividend of Rs 3 per share (30%) on equity shares for the financial year 2011-12.
The above information is part of company’s filing submitted to the BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1677.45 |
| Dr. Reddys Lab | 1229.00 |
| Cipla | 1230.00 |
| Zydus Lifesciences | 932.00 |
| Lupin | 2333.50 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: